GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ReNeuron Group PLC (OTCPK:RNUGF) » Definitions » Cash And Cash Equivalents

RNUGF (ReNeuron Group) Cash And Cash Equivalents : $6.28 Mil (As of Sep. 2023)


View and export this data going back to 2006. Start your Free Trial

What is ReNeuron Group Cash And Cash Equivalents?

ReNeuron Group's quarterly cash and cash equivalents declined from Sep. 2022 ($10.72 Mil) to Mar. 2023 ($7.47 Mil) but then stayed the same from Mar. 2023 ($7.47 Mil) to Sep. 2023 ($6.28 Mil).

ReNeuron Group's annual cash and cash equivalents declined from Mar. 2021 ($20.39 Mil) to Mar. 2022 ($12.58 Mil) and declined from Mar. 2022 ($12.58 Mil) to Mar. 2023 ($7.47 Mil).


ReNeuron Group Cash And Cash Equivalents Historical Data

The historical data trend for ReNeuron Group's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ReNeuron Group Cash And Cash Equivalents Chart

ReNeuron Group Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26.92 15.63 20.39 12.58 7.47

ReNeuron Group Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.68 12.58 10.72 7.47 6.28

ReNeuron Group Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


ReNeuron Group  (OTCPK:RNUGF) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


ReNeuron Group Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of ReNeuron Group's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


ReNeuron Group Business Description

Traded in Other Exchanges
N/A
Address
Pencoed Business Park, Pencoed, Bridgend, GBR, CF35 5HY
ReNeuron Group PLC is engaged in the field of biotechnology. Its core activities include the research and clinical development of cell-based therapeutics. The company product pipeline includes the human retinal progenitor cell line (hRPC) and CTX neural cell line. It derives revenue from UK and U.S. The company is mainly focusing on the treatment of stroke disability, inherited retinal diseases, and cancer.